Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Phase 2 Interventional

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

NCT00000794
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

NCT00002113
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 3 Interventional

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

NCT00002220
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder

NCT00316303
View directory record Official record
Conditions
HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression, Substance Abuse
Interventions
Twinrix, Enhanced treatment as usual
Drug · Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 17, 2026, 11:21 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mild Neurocognitive Disorder in HIV Infection of the Brain

NCT01547754
View directory record Official record
Conditions
HIV-Associated Cognitive Motor Complex
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NCT00002205
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005
View directory record Official record
Conditions
HIV Infections
Interventions
MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 17, 2026, 11:21 AM EDT
Completed No phase listed Observational

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

NCT05784415
View directory record Official record
Conditions
Leukemia, Leukemia, Lymphoblastic, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, HIV Associated Lymphoma, HIV Disease; Lymphoma
Interventions
Not listed
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 17, 2026, 11:21 AM EDT
Completed No phase listed Observational

Obesity in HIV After Antiretroviral Therapy

NCT01461876
View directory record Official record
Conditions
HIV, AIDS, Obesity
Interventions
antiretroviral therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Impact of an Educational HIV Prevention Intervention in Zambia

NCT03316040
View directory record Official record
Conditions
HIV/AIDS
Interventions
JIC
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 22 Years
Enrollment
8,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 17, 2026, 11:21 AM EDT
Recruiting No phase listed Observational

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants

NCT00039689
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)

NCT00691041
View directory record Official record
Conditions
HIV Infections
Interventions
Unity in Diversity
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Drug Interactions Among Anti-HIV Agents

NCT00001766
View directory record Official record
Conditions
HIV Infection
Interventions
Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients

NCT00002426
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
0 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
37
States / cities
Beverly Hills, California • Palm Springs, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Black Men Ages 14-19 Attracted to Men

NCT04135443
View directory record Official record
Conditions
HIV/AIDS and Infections, Sexual Behavior, Health Knowledge, Attitudes, Practice
Interventions
3T Tune in! Turn on! Turn up!, General Health Materials Website
Behavioral
Lead sponsor
ETR Associates
Other
Eligibility
14 Years to 19 Years · Male only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults

NCT00043511
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS2 Plasmid DNA Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Managed Problem Solving for ART Adherence and HIV Care Retention Delivered by Community Health Workers

NCT04560621
View directory record Official record
Conditions
HIV/AIDS
Interventions
Managed Problem Solving (MAPS)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Camden, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

NCT06266416
View directory record Official record
Conditions
Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Interventions
IMARA for Black Male Caregivers and Girls Empowerment, Time-matched control program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
13 Years and older
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

NCT00076063
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP1452), LIPO-5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 17, 2026, 11:21 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients

NCT00001116
View directory record Official record
Conditions
HIV Infections
Interventions
Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
Honolulu, Hawaii • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 11:21 AM EDT
Withdrawn Phase 1 Interventional

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

NCT05079451
View directory record Official record
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 11:21 AM EDT